The Conversation (0)
Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
Mar. 28, 2018 08:57AM PST
Pharmaceutical InvestingMersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other proprietary platforms, today reported financial results and a business update for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: “Our achievements in …
Mersana Therapeutics (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other proprietary platforms, today reported financial results and a business update for the fourth quarter and full year ended December 31, 2017.
As quoted in the press release:
“Our achievements in 2017 demonstrate our ability to build a transformative ADC pipeline of innovative oncology product candidates. Our two lead ADC product candidates, XMT-1522 and XMT-1536, have progressed through significant clinical milestones,” said Anna Protopapas, President and CEO of Mersana Therapeutics. “Overall, we are making great strides in achieving our vision of creating a significant difference in patients’ lives.”
